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Both raloxifene (RLX) and alendronate (ALN) can treat and
prevent new vertebral fractures, increase bone mineral den-
sity (BMD), and decrease biochemical markers of bone turn-
over in postmenopausal women with osteoporosis. This phase
3, randomized, double-blind 1-yr study assessed the effects of
combined RLX and ALN in 331 postmenopausal women with
osteoporosis (femoral neck BMD T-score, less than 2).
Women (aged <75 yr; >2 yr since their last menstrual period)
received placebo, RLX 60 mg/d, ALN 10 mg/d, or RLX 60 mg/d
and ALN 10 mg/d combined. At baseline, 6 and 12 months, BMD
was measured by dual x-ray absorptiometry. The bone turn-
over markers serum osteocalcin, bone-specific alkaline phos-
phatase, and urinary N- and C-telopeptide corrected for cre-
atinine were measured. The effects of RLX and ALN were
considered to be independent and additive if the interaction
effect was not statistically significant (P > 0.10) in a two-way
ANOVA model. All changes in BMD and bone markers at 12
months were different between placebo and each of the active
treatment groups, and between the RLX and RLXALN
groups (P < 0.05). On average, lumbar spine BMD increased by
2.1, 4.3, and 5.3% from baseline with RLX, ALN, and RLXALN,
respectively. The increase in femoral neck BMD in the
RLXALN group (3.7%) was greater than the 2.7 and 1.7%
increases in the ALN (P  0.02) and RLX (P < 0.001) groups,
respectively. The changes from baseline to 12 months in bone
markers ranged from 7.1 to 16.0% with placebo, 23.8 to
46.5% with RLX, 42.3 to 74.2% with ALN, and 54.1 to
81.0% in the RLXALN group. RLX and ALN increased lum-
bar spine and femoral neck BMD, and decreased osteocalcin
and C-telopeptide corrected for creatinine in an additive and
independent manner, because the interaction effects were not
significant. Although the ALN group had changes in BMD and
bone markers that were approximately twice the magnitude
as in the RLX group, it is not known how well these changes
correlate to the clinical outcome of fracture. RLXALN re-
duced bone turnover more than either drug alone, resulting in
greater BMD increment, but whether this difference reflects
better fracture risk reduction was not assessed in this study.
(J Clin Endocrinol Metab 87: 985–992, 2002)
THE ANTIRESORPTIVE AGENTS that are currently ap-proved in the United States for the prevention and
treatment of postmenopausal osteoporosis include estrogen
alone or combined with progestin in hormone replacement
therapy (HRT), the bisphosphonates alendronate (ALN) and
risedronate, salmon calcitonin nasal spray, and the selective
estrogen receptor modulator (SERM) raloxifene (RLX). Sev-
eral large, double-blind, placebo-controlled clinical trials of
postmenopausal women with established osteoporosis have
shown that ALN (1, 2), risedronate (3, 4), salmon calcitonin
(5), and RLX (6) significantly reduce the risk of vertebral
fractures. Each of these therapies increases bone mineral
density (BMD) to a different extent.
Previous studies have found that greater skeletal benefits
are obtained when two antiresorptive therapies are admin-
istered in combination, compared with either agent given
alone. Intermittent cyclic etidronate given in combination
with HRT increased lumbar spine BMD more than each
therapy given alone (7). Other studies found that women
treated with ALN combined with either conjugated equine
estrogens (8) or HRT (9) had greater BMD increases, com-
pared with women who received estrogen, HRT, or ALN
alone. In all of these studies, the number of fractures that
were reported in the combination therapy group was lower
than that found in the respective individual therapy groups.
However, none of these studies had adequate statistical
power to establish a greater decrease in fracture risk than
found with monotherapy.
Each antiresorptive therapy achieves its therapeutic effects
on bone through different modes of action. Bisphosphonates
bind to hydroxyapatite and inhibit bone resorption by de-
creasing the number and activity of osteoclasts (10). Al-
though the mechanisms of action of SERMs are not yet fully
understood, some factors that contribute to the tissue-
specific actions of SERMs include binding to estrogen re-
ceptor  and  isoforms, binding of the SERM-estrogen re-
ceptor complex to target genes, and modification of gene
expression by cellular proteins (11). For example, the tissue-
specific actions of RLX have been documented in clinical
trials. Increases in BMD and decreases in markers for bone
turnover (6, 12) and lipid metabolism (13, 14) are examples
Abbreviations: ALN, Alendronate; BCE, bone collagen equivalent;
BMD, bone mineral density; BSAP, bone-specific alkaline phosphatase;
Cr, creatinine; CTx, C-telopeptide; DXA, dual x-ray absorptiometry;
HRT, hormone replacement therapy; NTx, N-telopeptide; OC, osteo-
calcin; RLX, raloxifene; SERM, selective estrogen receptor modulator.
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of the estrogen-agonist effects of RLX. Compared with the
stimulation seen with estrogen therapies, RLX did not in-
crease endometrial thickness (15, 16) or breast density (17),
demonstrating estrogen-antagonist effects on these tissues.
Due to these different mechanisms of action, the present
study tests the hypothesis that the addition of ALN would
have an independent, additive effect on the changes in BMD
and bone turnover markers observed with RLX therapy
when these therapies are given in combination.
The primary objective of the present study was to evaluate
the effects of RLX and ALN, either alone or in combination,
compared with placebo, on lumbar spine and femoral neck
BMD and biochemical markers of bone metabolism in post-
menopausal women with osteoporosis.
Patients and Methods
Patients
Ambulatory women aged up to 75 yr, with their last menstrual period
at least 2 yr before study entry, were eligible for the study. Postmeno-
pausal status was verified in women who have not had a hysterectomy
by serum E2 levels less than 73 pmol/liter and FSH levels greater than
30 IU/liter. Women with femoral neck BMD greater than 2.0 sd below
peak bone mass for healthy premenopausal women were eligible, re-
gardless of the presence of prevalent vertebral fractures. Exclusion cri-
teria for this study included: current bone disorders other than primary
osteoporosis, any history of cancer in the previous 5 yr, active venous
thromboembolic disease, and endocrine disorders requiring pharmaco-
logic therapy, except type II diabetes. Women who received therapeutic
doses of any of the following medications before study entry were
excluded: androgen, calcitonin, estrogen and progestin in the past 6
months, systemic corticosteroids for at least 1 month in the past 12
months, bisphosphonates for at least 14 d in the past 18 months, any
bisphosphonates in the past 6 months, and fluoride (20 mg/d) for more
than 3 months during the past 2 yr. Women with upper gastrointestinal
problems requiring medical treatment within the past 12 months, or who
were currently treated with systemic lipid lowering agents, H2 blockers,
or proton pump inhibitors were excluded. Women signed a written
informed consent document before entering the study. Investigators
obtained local Institutional Review Board approval.
Study design
This phase 3, randomized, double-blind study was conducted at 30
study sites in Australia, Belgium, Canada, Italy, Mexico, South Africa,
Spain, and Sweden. A total of 331 women were randomly assigned in
blocks of four to one of the following groups: placebo, RLX HCl 60 mg/d
in tablet form, ALN sodium 10 mg/d in capsule form, or a combination
of RLX (60 mg/d) and ALN (10 mg/d). All women received a supple-
ment containing approximately 500 mg/d elemental calcium and vita-
min D 400–600 IU/d. Placebo was provided in tablets identical in
appearance to RLX and in capsules identical in appearance to ALN
(double dummy). Women were instructed to take one capsule and one
tablet of the blinded study medication. According to the prescribing
information for ALN, the capsule was to be taken upon waking in the
morning with a large glass of water, and no food or drink was to be taken
for 30 min afterward. The tablet, along with the calcium and vitamin D
supplement, was taken at least 30 min after the capsule. The study
medication and placebo were packaged in kits numbered according to
a random-number table. At randomization, kits were assigned sequen-
tially to each woman, beginning with the lowest number available.
Methods
Lumbar spine and femoral neck BMD were measured by dual x-ray
absorptiometry (DXA) at baseline and at 6-month intervals, using either
Hologic QDR (Hologic, Inc., Waltham, MA), Lunar DPX (Lunar Corp.











Age (yr) 63.8  5.3 63.4  6.3 63.7  6.0 63.8  6.3 0.97
BMI (kg/m2) 24.3  3.9 24.8  3.8 24.8  3.8 25.0  3.8 0.71
Years postmenopausal 17.6  8.2 15.6  7.7 16.5  7.7 17.1  9.0 0.44
Previous use of HRT 41% 32% 36% 24% 0.12
Hysterectomy 28.0% 24.7% 28.9% 19.0% 0.45
Estimated dietary calcium intake (mg/d) 740  485 675  425 830  480 770  410 0.17
Lumbar spine BMD (g/cm2) 0.76  0.13 0.77  0.12 0.78  0.14 0.76  0.12 0.59
Femoral neck BMD (g/cm2) 0.62  0.09 0.62  0.07 0.62  0.08 0.61  0.08 0.39
OC (g/liter) 23.6  8.6 25.9  11.7 25.9  11.6 24.7  10.6 0.58
BSAP (g/liter) 14.6  6.2 14.6  6.0 14.5  6.4 14.5  6.5 0.77
CTx/Cr (g/mmol) 277.6  149.6 299.8  147.1 288.9  140.2 258.6  136.3 0.27
NTx/Cr (nmol/mmol) 50.6  25.9 53.2  24.2 54.3  31.4 52.8  29.5 0.89
BMI, Body mass index; NTx, cross-linked N-telopeptide of type I collagen; CTx, cross-linked C-telopeptide of type I collagen (Crosslaps).
a Values obtained at randomization were expressed as mean SD. N represents number of women randomized, except for BMD measurements
where n  77 in each group.
TABLE 2. Percentage changes in BMD and biochemical markers from baseline to 1 yra
Endpoint Placebo RLX ALN RLX  ALN
Lumbar spine BMD 0.004  0.3 2.1  0.4b,c,d,e 4.3  0.4b,c 5.3  0.4b,c
Femoral neck BMD 0.2  0.4 1.7  0.4b,c,d,e 2.7  0.5b,c,e 3.7  0.5b,c
OC 1.2 25.7b,c,d,e 42.3b,c 54.3b,c
BSAP 11.8b 32.2b,c,d,e 52.1b,c 54.1b,c
CTx/Cr 16.0 46.5b,c,d,e 74.2b,c 81.0b,c
NTx/Cr 7.1b 23.8b,c,d,e 58.4b,c 63.3b,c
a BMD values are mean percentage change  SEM. Values for the biochemical markers of bone turnover are median percentage change.
b Statistically significantly different from baseline.
c Statistically significantly different from placebo.
d Statistically significantly different from ALN.
e Statistically significantly different from RLX  ALN.
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Radiation, Madison, WI), or Norland (Norland Medical Systems, Inc.,
White Plains, NY) densitometers. For each study site and DXA device, a
Hologic, Inc. anthropomorphic spine phantom was used as daily quality
control, and phantom cross-calibration data were used to correct in vivo
values and to standardize all BMD measurements. Each DXA scan was
reviewed and evaluated by a central laboratory (Synarc, Portland, OR). If
any differences existed among the DXA machines or due to longitudinal
drifting of densitometers over time, the central laboratory adjusted for these
differences by use of correction factors. Biochemical markers of bone me-
tabolism were measured at baseline and at 1, 6, and 12 months. The markers
included serum osteocalcin (OC) (ELSA-IRMA, CIS Biointernational, Gif-
sur-Yvette, France), serum bone-specific alkaline phosphatase (BSAP) (Os-
tase IRMA, Hybritech, San Diego, CA), urinary N-telopeptide (NTx) (Ostex
International, Inc., Seattle, WA), and C-telopeptide (CTx) (Crosslaps, Os-
teometer A/S, Herlev, Denmark) fragments of type I collagen normalized
to creatinine (Cr) excretion. All biochemical marker assays were analyzed
at a central laboratory (Covance, Indianapolis, IN, and Geneva, Switzer-
land). The premenopausal and postmenopausal reference ranges for
NTx/Cr were 5.0–65.0 nm bone collagen equivalents (BCE)/mmol and
0.0–130.0 nm BCE/mmol, respectively. For CTx/Cr, the premenopausal
and postmenopausal reference ranges were 52.02–779.99 g/mmol and
58.13–882.04 g/mmol, respectively.
At each clinic visit, women were questioned about the occurrence and
nature of adverse events. All adverse events reported at each postbaseline
visit were recorded. Hot flashes associated with RLX therapy may be
reported as vasodilatation or sweating. Esophageal or gastric irritation
associated with ALN therapy may be reported as substernal chest or ab-
dominal pain.
FIG. 1. Mean percentage changes SEM in lumbar spine and femoral neck BMD after 6 and 12 months of treatment with placebo (PL, circles),
RLX 60 mg/d (squares), ALN 10 mg/d (triangles), or combined RLX and ALN (diamonds). Asterisks (*) indicate statistically significant changes
from baseline (P  0.05).
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Statistical analyses
All data analyses were performed on an intent-to-treat basis in
women who had at least one follow-up visit. For continuous data, such
as BMD and biochemical markers of bone turnover, the percentage
change from baseline to endpoint within each group was analyzed using
t test. The ANOVA model, with fixed effects for therapy and investi-
gator, evaluated the differences between treatment groups. Pair-wise
comparisons were performed using contrast statements in the ANOVA
model. For categorical data such as adverse events, Pearson’s 2 test was
used to test treatment group differences. Statistical inferences were
made on the basis of two-sided, significance level of P  0.05.
To test for possible additive effects of RLX and ALN, a two-way
ANOVA model with RLX treatment, ALN treatment, and the interaction
of the two treatments was used to evaluate the percentage changes in
BMD and biochemical markers. Treatment additivity, defined as the
sum of the interaction between the two treatments, was tested at the
significance level of P  0.10. When the interaction was not statistically
significant (P  0.10), the effects of RLX and ALN were considered to
be independent of each other, and the effects of RLX and ALN were
additive when given in combination.
Results
The women had a mean age of 63.6 yr, an average of 16.7
yr after their final menstrual period, and a mean body mass
index of 24.7 kg/m2. Ninety-five percent of the women were
FIG. 2. Mean percentage changes  SEM in the biochemical markers of bone turnover: osteocalcin (A), bone-specific alkaline phosphatase (B),
N-telopeptide (C) and C-telopeptide (D), both normalized to creatinine. Bone turnover markers were measured after 6 and 12 months of
treatment with placebo (PL, circles), RLX 60 mg/d (squares), ALN 10 mg/d (triangles) or combined RLX and ALN (diamonds). Asterisks (*)
indicate statistically significant changes from baseline (P  0.05).
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white. There were no differences in baseline characteristics
among the groups (Table 1). Of the 331 women enrolled, 274
(82.8%) completed the study. There were no differences
among the groups in the overall discontinuation rate or in
any specific reason for discontinuation.
At 1 yr, lumbar spine and femoral neck BMD in the active
treatment groups significantly increased from baseline (Fig. 1),
and these increases were also significantly greater than placebo
(Table 2). The increase in lumbar spine BMD at 1 yr in the
combination group did not differ from that in the ALN group
(P 0.10). The 4.3% increase in lumbar spine BMD with ALN
was different from the 2.1% increase in the RLX group (P 
FIG. 2. Continued
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0.001). The increase in femoral neck BMD in the combination
group at 1 yr was greater than the increases in both the ALN
(P  0.02) and RLX (P  0.001) groups (Table 2). The 2.7%
increase in femoral neck BMD with ALN was different from the
1.7% increase in the RLX group (P  0.03). BMD at the tro-
chanter, intertrochanter, and Ward’s triangle increased by 3.9,
2.3, and 4.4%, respectively, in the ALN group. The combination
group had increases of 3.9, 2.4, and 4.6% in the trochanter,
intertrochanter, and Ward’s triangle, respectively, at 1 yr. These
increases were not different between the ALN and combination
groups, but were statistically significantly different from the
changes in the placebo and RLX groups.
The biochemical markers of bone turnover, OC, BSAP,
CTx/Cr, and NTx/Cr in all treatment groups decreased from
baseline (Fig. 2) and differed from placebo (Table 2) at 1 yr.
The decreases in OC, BSAP, and CTx/Cr were approxi-
mately 1.6-fold greater in the ALN group, compared with the
RLX group (P  0.02). The decrease in NTx/Cr was 2.5-fold
greater in the ALN group than in the RLX group (P 0.001).
None of the decreases in bone markers differed between the
ALN and combination groups, but both had greater de-
creases than the RLX group (Table 2). The percentage of
women with postbaseline CTx/Cr values below the lower
limit of the premenopausal range (52.02 g/mmol) was sig-
nificantly greater with ALN (52.6%) than with placebo (3.8%)
or RLX (13.9%), and was similar to that observed in the
combination (56.2%) group (each treatment P  0.05 from
placebo). Only one woman in the combination therapy group
had a postbaseline NTx/Cr value below the lower limit of the
premenopausal range (5.0 nm BCE/mmol), and the between-
group difference was not statistically significant.
To determine whether the effects of RLX and ALN were
independent and additive in combination, the groups with
RLX (alone and combined with ALN) and without RLX (pla-
cebo and ALN) were compared. A visual assessment for
additive effects showed no intersection of the lines connect-
ing the groups with RLX and those without RLX (Fig. 3),
suggesting that RLX and ALN act independently on BMD
and the effects were additive. A two-way ANOVA model
supported these observations, where the interaction of the
two treatments was not significant (P 0.10). Combined RLX
and ALN have independent and additive effects on the
changes in lumbar spine and femoral neck BMD, OC and
CTx/Cr (Table 3), but not on changes in BSAP and NTx/Cr
because the interaction terms were significant (P  0.10).
There were no statistically significant differences among
the groups in the incidences of any of the adverse events that
may be associated with either RLX or ALN therapy (Table 4).
The differences in discontinuation rates were not statistically
significant among the groups.
Discussion
RLX and ALN, alone or in combination, increased lumbar
spine and femoral neck BMD and decreased all biochemical
markers of bone turnover, compared with baseline and pla-
cebo in healthy postmenopausal women with osteoporosis.
The effects of ALN alone and in combination with RLX on
FIG. 3. Mean percentage changes in lumbar spine and
femoral neck BMD at 12 months in the groups that did
not have RLX (circles) were compared with the groups
that had RLX (squares). The groups that did not have
RLX were the placebo and ALN groups. There was no
intersection of the lines joining the groups that did or
did not have RLX, suggesting that the effects of each
treatment on BMD were additive and independent of
each other.
TABLE 3. The additive effects of RLX and ALN on BMD and biochemical markers of bone turnover
Variable RLXa ALNa RLX  ALNInteractiona Additive?
b
Lumbar spine BMD 0.001 0.001 0.153 Yes
Femoral neck BMD 0.008 0.001 0.654 Yes
OC 0.001 0.001 0.150 Yes
BSAP 0.009 0.001 0.078 No
CTx/Cr 0.001 0.001 0.499 Yes
NTx/Cr 0.001 0.001 0.053 No
a P values were obtained from a two-way ANOVA analysis model on rank transformed data.
b The effects of RLX and ALN were considered to be additive and independent of each other if the interaction effect was not statistically
significant (P  0.10).
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all BMD and bone marker endpoints were significantly
greater than those observed with RLX alone. Except for the
increase in femoral neck BMD, the effects of the combined
therapy group were not significantly different from those
observed with ALN alone. The doses of RLX and ALN used
in this study are the currently marketed doses. Although
higher doses of RLX (6, 18, 19) and ALN (20, 21) have been
studied in other clinical trials, the combined effects of the
other doses of these therapies are not known.
The combined effects of RLX and ALN on lumbar spine
and femoral neck BMD, OC, and CTx/Cr were considered to
be independent and additive, because the interaction effects
were not significant (P  0.10). However, the effects of RLX
and ALN were not found to be independent and additive
with the other bone formation (BSAP) and resorption (NTx/
Cr) markers. The proportion of women who had CTx/Cr
values below the lower limit of the premenopausal range was
significantly greater in the groups treated with ALN com-
pared with placebo and RLX. The reasons for these contrast-
ing observations are not clear, but the known variability in
bone marker measurements may contribute to these findings
(22). The independent and additive results observed in this
study are suggestive of different actions of RLX and ALN at
the cellular level, although the nature of these actions re-
mains to be determined.
The present results with combined RLX and ALN are
similar to those reported with other combinations of antire-
sorptive agents. At 1 yr, combined RLX and ALN increased
lumbar spine and femoral neck BMD by 5.3 and 3.7% from
baseline, respectively. Combinations of HRT with etidronate
(7) and of conjugated equine estrogens with ALN (8) also
increased lumbar spine and femoral neck BMD by about 6
and 4% from baseline, respectively. Addition of ALN to
existing HRT increased lumbar spine and femoral neck BMD
by 3.6 and 1.7% from baseline, respectively (9). Women
treated with risedronate combined with HRT had increases
in lumbar spine and femoral neck BMD of 3.8 and 2.6% from
baseline, respectively (23).
Bone histomorphometry studies determined that combined
administration of antiresorptive therapies was not associated
with any adverse changes in bone quality. Bone biopsies from
women treated with conjugated equine estrogens and ALN, (8),
with HRT and etidronate, (7), or with HRT and risedronate, (23)
alone or in combination, had normal mineralization and bone
quality. Although the present study did not examine the com-
bined effects of RLX and ALN on bone quality, bone biopsies
from women treated with RLX (24) or ALN alone (25) had
normal bone quality and mineralization.
Although histomorphometry shows normal bone quality at
the cellular level, severe reductions in bone turnover produced
by antiresorptive therapies may indirectly lead to an increased
risk of fractures (26). Normal mechanical loading results in
microarchitectural deformities, which are repaired during the
bone remodeling process. If these deformities are not repaired
in so-called frozen bone, which has a very low bone remodeling
rate, the accumulation of deformities can theoretically contrib-
ute to bone fragility and possibly fracture (26). The present
evidence to support this theory is not conclusive and has only
been demonstrated in dogs treated with doses of bisphospho-
nates several times higher than those used clinically (27–29). In
the present study, combined RLX and ALN reduced bone turn-
over markers 54–81%, a range of effects similar to those pro-
duced by administering estrogen in combination with ALN (8).
Although over 50% of women in the ALN and combination
therapy groups had postbaseline CTx/Cr values below the
lower limit of the normal premenopausal range, the clinical
relevance of this observation is not known. It is not known
whether the levels of suppression of bone remodeling observed
with combined antiresorptive therapy in women can produce
an accumulation of microarchitectural deformities, which can
lead to an increased risk of fracture.
None of the published studies of combined antiresorptive
therapies had adequate statistical power to demonstrate a
greater decrease in fracture risk with combination therapy,
compared with either therapy alone. For example, the inci-
dence of fractures in the combined conjugated equine estro-
gens and ALN group (5.7%) was similar to that observed in
the groups with estrogens (6.9%) or ALN (5.4%) alone (8).
The incidence of fractures was 7.0% in women who received
ALN along with existing HRT and 4.2% in women who
received HRT alone (9). The incidence of new vertebral frac-
tures in the combined risedronate and HRT group (1.8%) was
not statistically different from the 2.6% observed in the group
treated with HRT alone (23). The present study also did not
have adequate statistical power to determine antifracture
efficacy of combined RLX and ALN.
Some women do not respond and lose BMD when given one
antiresorptive agent (30), so it is tempting to consider a com-
bination of antiresorptive therapies. Although there are possi-
ble BMD benefits of combined therapy, fracture efficacy data
are lacking. Other factors that should be considered include the
extraskeletal benefits associated with each therapy and the pa-
tient’s concomitant illnesses or risk factors for other disorders.
An increase in the incidence, severity, or types of adverse events
is possible with combination therapy. Most importantly, the
additional costs involved with combination therapy may be








(N  84) P value
b
Vasodilatation 4.9% 4.9% 4.8% 4.8% 1.00
Sweating 2.4% 1.2% 2.4% 0% 0.52
Chest pain substernal 2.4% 4.9% 7.2% 3.6% 0.49
Abdominal pain 6.1% 7.3% 10.8% 6.0% 0.60
Discontinuations due to adverse event 4.9% 8.5% 9.6% 6.0% 0.61
PL, placebo.
a Hot flashes associated with RLX therapy may be reported as vasodilatation or sweating. Esophageal or gastric irritation associated with
ALN therapy may be reported as substernal chest or abdominal pain.
b Overall P value among all treatment groups as calculated by Pearson’s 2 test.
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prohibitive for some patients. The patient and physician should
carefully weigh the risks and benefits of combined antiresorp-
tive therapy before deciding on such a regimen.
In summary, RLX and ALN alone and in combination in-
creased lumbar spine and femoral neck BMD and decreased all
biochemical markers of bone turnover. The combination of
ALN and RLX produced a greater increase in femoral neck
BMD compared with either agent alone. Although the increases
in lumbar spine BMD and changes in bone turnover markers
with ALN alone and in combination therapy were similar and
greater than that observed with RLX alone, the effects of com-
bined RLX and ALN on BMD were independent and additive.
The effect of combined RLX and ALN on fracture risk is un-
known. The long-term clinical safety of combination therapy on
the risk of fracture remains to be determined.
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